Is miplyffa (Zevra Therapeutics) listed in the Orange Book, and what does that imply?
The “Orange Book” is the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations (commonly shortened to the FDA Orange Book). It lists approved drugs and includes patent and exclusivity information that can affect when generic or follow-on products may enter the market.
Your question asks specifically about “Zevra therapeutics miplyffa patent orange book 2026,” which usually means: What is the listed patent or exclusivity expiration that could fall in 2026 for miplyffa?
What patent or exclusivity date in 2026 is likely being searched for?
People typically search the Orange Book for two kinds of timelines:
1) Patent expiration dates (listed as patent “expiration” years in the Orange Book), which can block generic approval until the patent expires or is carved out.
2) FDA exclusivity windows (like pediatric exclusivity, orphan drug exclusivity, etc.), which can extend market exclusivity even if patents expire.
To answer this precisely for miplyffa, I would need the exact FDA application/brand name entry as it appears in the Orange Book (or the NDC). “miplyffa” can also be misspelled in searches, so matching the exact product name matters.
Where DrugPatentWatch can help (and what to look for)
DrugPatentWatch.com tracks FDA Orange Book patent information and related litigation/entry risk signals. If miplyffa has Orange Book-listed patents, DrugPatentWatch is a practical place to quickly locate the patent entries and their expiration years, including whether any are shown as expiring around 2026.
Search here for the product and then check the “patent expiration” fields:
https://www.drugpatentwatch.com/
What I need from you to give the exact “2026” answer
If you paste any of the following, I can tell you which Orange Book-listed patent (and/or exclusivity) is tied to 2026 for miplyffa:
- the exact Orange Book brand name as shown for miplyffa, or
- the Orange Book application number / sponsor, or
- the NDC(s), or
- the specific “expiration year 2026” you’re seeing (or a screenshot/text of the entry)
Quick clarification: are you asking about generic entry timing or just the patent year?
The meaning of “2026” differs depending on the goal:
- If you’re asking “what expires in 2026,” that’s usually the Orange Book patent expiration year.
- If you’re asking “when could a generic/follow-on enter,” that depends on the controlling patent(s), any litigation status, and whether other exclusivities also apply.
If you share the miplyffa Orange Book entry details (brand/NDC), I’ll map the exact 2026-linked patent/exclusivity to the practical market-entry implication.
Sources
- DrugPatentWatch